slides · global inventory
Consultants Gambit
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 39,432
Current window 31,981-32,010
Pages 1,315
Rows per page 30
Arc
31,981-32,010 of 39,432
01
The infinity symbol is used as a framing device for the imagery.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
02
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
03
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
04
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
05
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
06
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Situation & Context1 hit
24
The slide uses a structured layout to define the disease state and market opportunity.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
25
The diagram uses a bubble-cluster visualization to show the relationship between different autoantibodies and clinical conditions.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
26
The slide uses a circular process flow to explain the pathology of Immune-Mediated Necrotizing Myopathy (IMNM).argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
27
The slide uses a process-flow framework to show how autoantibodies trigger specific biological pathways (myolysis, capillary disruption, interferon production) leading to muscle atrophy.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
28
The diagram illustrates a hub-and-spoke model where the autoantibody is the central mediator.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Problem & ComplicationLoop · Cost Of Inaction1 hit
29
The slide illustrates the diversity of autoantibodies in myositis patients, supporting the thesis that a broad-acting therapy like Efgartigimod is effective.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
30
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
31
The slide shows 8 individual patient longitudinal plots. Each plot has dual y-axes (CK and Anti-SRP54) and a shared x-axis (Days).argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
32
The chart is a Kaplan-Meier survival curve showing 'DOI-free Survival Probability' over time in weeks.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
33
ProDERM study data comparing IVIg and placebo efficacy over time.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
34
Includes two dot plots showing grip/muscle strength and two microscopy images showing necrosis and complement deposition.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
35
The chart uses a diagonal line to represent growth or accumulation of patient segments.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
36
The slide outlines a clinical trial protocol involving 180 patients, stratified by condition and severity, with a 26-week duration and specific primary/secondary endpoints.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
37
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
38
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
39
The slide uses a structured 4-column layout to summarize the disease profile.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
40
The slide depicts a step-by-step biological pathway (1-6) showing how autoantibodies lead to blister formation. It also highlights the therapeutic target Efgartigimod.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
41
The slide uses a before-after structure to contrast WT mice (susceptible) with FcRn-/- mice (resistant) and shows the impact of HDIG treatment.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
42
The funnel structure implies a progression toward higher selectivity and better outcomes.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
43
The slide presents three distinct clinical datasets (IVIg, Protein A Immunoadsorption, and PLEX) to support the thesis that IgG-targeted therapies lead to fast remissions.argenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Evidence & ProofLoop · Aha Moment1 hit
46
argenx SE | Investor Day Presentation Deck | 69 slidesargenx SE | Investor Day Presentation Deck | 69 slides · argenx
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
61
WPP | ESG Presentation Deck | 63 slidesWPP | ESG Presentation Deck | 63 slides · WPP
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
62
WPP | ESG Presentation Deck | 63 slidesWPP | ESG Presentation Deck | 63 slides · WPP
Conference presentation Investor relations Beat · Impact & Next Steps1 hit
63
WPP | ESG Presentation Deck | 63 slidesWPP | ESG Presentation Deck | 63 slides · WPP
Conference presentation Investor relations Beat · Impact & Next Steps1 hit